Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review

References

• Barik D, Arokiasamy P. Rising health expenditure due to non-communicable diseases in India: an outlook. Front Public Health. 2016;4:223549. doi: 10.3389/fpubh.2016.00268
   Web of Science ®Google Scholar
• Irandoust K, Esmaiil Zali M, Parvari A, et al. Epidemiological study of the prevalence of death in older adults receiving home treatment services in Tehran Using ICD-10, 2012-2016. J Mazandaran Univ Med Sci. 2021;31(197):190–196.
   Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. England: Oxford university press; 2015.
   Google Scholar
• Afshari S, Ameri H, Daroudi RA, et al. Health related quality of life in adults with asthma: a systematic review to identify the values of EQ-5D-5L instrument. J Asthma. 2022;59(6):1203–1212. doi: 10.1080/02770903.2021.1917607
   PubMed Web of Science ®Google Scholar
• Afshari S, Ameri H, Baharinya S, et al. Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2022 Feb 17;22(2):351–364. doi: 10.1080/14737167.2022.2011216
   PubMed Web of Science ®Google Scholar
• Silari M. Applications of particle accelerators in medicine. Radiation protection dosimetry. 2011;146(4):440–50.
   PubMed Web of Science ®Google Scholar
• Huang J. Boron neutron capture therapy for cancer treatments. Guildford: University of Surrey; 2009.
   Google Scholar
• Drugs CAf, Health Ti. TomoTherapy, Gamma Knife, and CyberKnife therapies for patients with tumours of the lung, central nervous system, or intra-abdomen: a systematic review of clinical effectiveness and cost-effectiveness. CADTH Technol Overv. 2010;1(3):14–40.
   Google Scholar
• Langlois A-M, Iorio-Morin C, Masson-Côté L, et al. Gamma knife stereotactic radiosurgery for nonvestibular cranial nerve schwannomas. World Neurosurg. 2018;110:e1031–e1039. doi: 10.1016/j.wneu.2017.11.163
   PubMed Web of Science ®Google Scholar
• Denny DS, Allen DK, Worthington N, et al. The use of failure mode and effect analysis in a radiation oncology setting: the cancer treatment centers of America experience. J Healthc Qual. 2014;36(1):18–28. doi: 10.1111/j.1945-1474.2011.00199.x
   PubMed Web of Science ®Google Scholar
• Hoffelt SC. Gamma knife vs. cyberKnife. Oncology Issues. 2006;21(5):18–20. doi: 10.1080/10463356.2006.11883284
   Google Scholar
• Kim CH, Im YS, Nam DH, et al. Gamma knife radiosurgery for ten or more brain metastases. J Korean Neurosurg Soc. 2008 Dec;44(6):358–363. doi: 10.3340/jkns.2008.44.6.358
   PubMed Web of Science ®Google Scholar
• Miller R, Van Houten H, Foote R, et al. Understanding the characteristics and types of adult and pediatric cancers treated with proton beam radiation therapy in a population of 88 million commercially insured patients. Int J Radiat Oncol Biol Phys. 2014;90(1):S64. doi: 10.1016/j.ijrobp.2014.05.217
   Google Scholar
• Alonso-Basanta M, Lustig RA, Kennedy DW. Proton beam therapy in skull base pathology. Otolaryngol Clin North Am. 2011;44(5):1173–1183. doi: 10.1016/j.otc.2011.08.012
   PubMed Web of Science ®Google Scholar
• Ma X, Lin C, Zhen W. Cancer care in China: A general review. Biomedical Imaging and Intervention Journal. 2008:4(3):1–8.
   Google Scholar
• NICE Evidence Reviews Collection. Evidence reviews for the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC: lung cancer: diagnosis and management: evidence review D. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2019; 2019.
   Google Scholar
• Tipton KN, Sullivan N, Bruening W, et al. AHRQ Comparative Effectiveness Technical Briefs. Stereotactic body radiation therapy. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011.
   Google Scholar
• Khan K, Kunz R, Kleijnen J, et al. Systematic reviews to support evidence-based medicine. 2nd ed. Taylor & Francis Group; 2011.
   Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10–31. doi: 10.1016/j.jval.2021.10.008
   PubMed Web of Science ®Google Scholar
• Wu X, Uhlig J, Blasberg JD, et al. Microwave ablation versus stereotactic body radiotherapy for stage I non–small cell lung cancer: a cost-effectiveness analysis [ Article]. J Vasc Interv Radiol. 2022;33(8):964–971.e2. doi: 10.1016/j.jvir.2022.04.019
   PubMed Web of Science ®Google Scholar
• Okazaki S, Shibuya K, Takura T, et al. Cost-effectiveness of carbon-ion radiotherapy versus stereotactic body radiotherapy for non-small-cell lung cancer. Cancer Sci. 2022 Feb;113(2):674–683. doi: 10.1111/cas.15216
   PubMed Web of Science ®Google Scholar
• Lourenco RDA, Khoo T, Crothers A, et al. Cost-effectiveness of single versus multifraction SABR for pulmonary oligometastases: the SAFRON II Trial [article]. Int J Radiat Oncol Biol Phys. 2022;114(5):968–976. doi: 10.1016/j.ijrobp.2022.01.024
   PubMed Web of Science ®Google Scholar
• Li G, Xia YF, Huang YX, et al. Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: is it cost-effective? Prostate. 2022 Nov;82(15):1438–1446. doi: 10.1002/pros.24417
   PubMed Web of Science ®Google Scholar
• Donovan EK, Xie F, Louie AV, et al. Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) versus stereotactic body radiotherapy (SBRT) for early stage renal cell carcinoma (RCC). Clin Genitourin Cancer. 2022 Oct;20(5):e353–e361. doi: 10.1016/j.clgc.2022.03.011
   PubMed Web of Science ®Google Scholar
• Arruda GV, Lourenção M, de Oliveira JHC, et al. Cost-effectiveness of stereotactic body radiotherapy versus conventional radiotherapy for the treatment of surgically ineligible stage I non-small cell lung cancer in the Brazilian public health system [article]. Lancet Reg Health - Am. 2022;14:14. doi: 10.1016/j.lana.2022.100329
   Google Scholar
• Raymakers AJN, Cameron D, Tyldesley S, et al. Cost-effectiveness analysis of stereotactic ablative body radiotherapy for the treatment of oligometastatic Tumors versus standard of care. Current Oncol. 2021 Jun;28(3):1857–1866. doi: 10.3390/curroncol28030172
   PubMed Web of Science ®Google Scholar
• Mehrens D, Unterrainer M, Corradini S, et al. Cost-effectiveness analysis of local treatment in Oligometastatic disease. Front Oncol. 2021 Jun;11:11. doi: 10.3389/fonc.2021.667993
   Google Scholar
• Leung HWC, Lang HC, Wang SY, et al. Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck. Expert Rev Pharmacoecon Outcomes Res. 2021 May;21(3):487–493. doi: 10.1080/14737167.2021.1890585
   Web of Science ®Google Scholar
• Jin H, Chalkidou A, Hawkins M, et al. Cost-effectiveness analysis of stereotactic ablative body radiation therapy compared with surgery and radiofrequency ablation in two patient cohorts: metastatic liver cancer and hepatocellular carcinoma [article]. Clin Oncol. 2021;33(3):e143–e154. doi: 10.1016/j.clon.2020.08.010
   Web of Science ®Google Scholar
• Alyamani N, Song J, van Katwyk S, et al. Cost-utility analysis of radiation treatment modalities for intermediate-risk prostate cancer. Current Oncol. 2021 Aug;28(4):2385–2398. doi: 10.3390/curroncol28040219
   PubMed Web of Science ®Google Scholar
• Wolff HB, Alberts L, van der Linden N, et al. Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study. Lung Cancer Journal. 2020;141:89–96.
   PubMed Web of Science ®Google Scholar
• Tran AD, Fogarty G, Nowak AK, et al. Cost-effectiveness of subsequent whole-brain radiotherapy or hippocampal-avoidant whole-brain radiotherapy versus stereotactic radiosurgery or surgery alone for treatment of melanoma brain metastases. Appl Health Econ Health Pol. 2020 Oct;18(5):679–687. doi: 10.1007/s40258-020-00560-1
   PubMed Web of Science ®Google Scholar
• Kumar A, Straka CA, Vitzthum L, et al. Cost-effectiveness analysis of stereotactic ablative radiotherapy in patients with oligometastatic cancer. J Clin Oncol. 2020 May;38(15):7085–7085. doi: 10.1200/JCO.2020.38.15_suppl.7085
   Web of Science ®Google Scholar
• Kim H, Vargo JA, Ling DC, et al. Cost-effectiveness analysis of upfront SBRT for oligometastatic stage IV non-small Cell lung cancer based on mutational status. Am J Clin Oncol. 2019 Nov;42(11):837–844. doi: 10.1097/COC.0000000000000608
   PubMed Web of Science ®Google Scholar
• Parikh ND, Marshall VD, Green M, et al. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: an analysis of SEER-medicare. J Med Imaging Radiat Oncol. 2018 Oct;62(5):673–681. doi: 10.1111/1754-9485.12754
   PubMed Web of Science ®Google Scholar
• Paix A, Noel G, Falcoz P-E, et al. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer. Radiother Oncol. 2018;128(3):534–540. doi: 10.1016/j.radonc.2018.04.013
   PubMed Web of Science ®Google Scholar
• Kim H, Vargo JA, Beriwal S, et al. Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. Head Neck. 2018 Aug;40(8):1743–1751. doi: 10.1002/hed.25142
   PubMed Web of Science ®Google Scholar
• Horáková D, Donin G, editors. Economic evaluation of robotic radiosurgery system for prostate cancer treatments in the Czech Republic. In: World Congress on Medical Physics and Biomedical Engineering 2018: June 3-8, 2018. Vol. 2. Prague, Czech Republic: Springer; 2019.
   Google Scholar
• Pollom EL, Lee K, Durkee BY, et al. Cost-effectiveness of stereotactic body radiation therapy versus radiofrequency ablation for hepatocellular carcinoma: a Markov modeling study. Radiology. 2017 May;283(2):460–468. doi: 10.1148/radiol.2016161509
   PubMed Web of Science ®Google Scholar
• Leung HWC, Chan ALF. Cost-utility of stereotactic radiation therapy versus proton beam therapy for inoperable advanced hepatocellular carcinoma. Oncotarget. [2017 Sep 26];8(43):75568–75576. doi: 10.18632/oncotarget.17369
   PubMedGoogle Scholar
• Kim H, Rajagopalan MS, Beriwal S, et al. Cost-effectiveness analysis of stereotactic radiosurgery alone versus stereotactic radiosurgery with upfront whole brain radiation therapy for brain metastases. Clin Oncol (R Coll Radiol). 2017 Oct;29(10):e157–e164. doi: 10.1016/j.clon.2017.05.001
   PubMed Web of Science ®Google Scholar
• Helou J, Torres S, Musunuru HB, et al. Stereotactic body radiotherapy versus low dose rate brachytherapy for localised prostate cancer: a cost-utility analysis. Clin Oncol (R Coll Radiol). 2017 Nov;29(11):718–731. doi: 10.1016/j.clon.2017.08.002
   PubMed Web of Science ®Google Scholar
• Wernicke AG, Yondorf MZ, Parashar B, et al. The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors. J Neurooncol. 2016 Mar;127(1):145–153. doi: 10.1007/s11060-015-2026-4
   PubMed Web of Science ®Google Scholar
• Leung HWC, Liu CF, Chan ALF. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. Radiat Oncol. 2016 May;11(1):11. doi: 10.1186/s13014-016-0644-4
   PubMedGoogle Scholar
• Leung HWC, Chan ALF, Muo CH. Cost-effectiveness of gemcitabine plus modern radiotherapy in locally advanced pancreatic cancer. Clin Ther. 2016 May;38(5):1174–1183. doi: 10.1016/j.clinthera.2016.03.005
   PubMed Web of Science ®Google Scholar
• Lester-Coll NH, Rutter CE, Bledsoe TJ, et al. Cost-effectiveness of surgery, stereotactic body radiation therapy, and systemic therapy for pulmonary oligometastases. Int J Radiat Oncol Biol Phys. 2016 Jun;95(2):663–672. doi: 10.1016/j.ijrobp.2016.01.020
   PubMed Web of Science ®Google Scholar
• Lester-Coll NH, Dosoretz AP, Magnuson WJ, et al. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases. J Neurosurg. 2016 Dec;125(Supplement_1):18–25. doi: 10.3171/2016.7.GKS161499
   PubMedGoogle Scholar
• Kim H, Gill B, Beriwal S, et al. Cost-effectiveness analysis of stereotactic body radiation therapy compared with radiofrequency ablation for inoperable colorectal liver metastases. Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1175–1183. doi: 10.1016/j.ijrobp.2016.02.045
   PubMed Web of Science ®Google Scholar
• Smith BD, Jiang J, Chang JY, et al. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. J Geriatr Oncol. 2015;6(4):324–331. doi: 10.1016/j.jgo.2015.05.002
   PubMed Web of Science ®Google Scholar
• Savitz ST, Chen RC, Sher DJ. Cost-effectiveness analysis of neurocognitive-sparing treatments for brain metastases. Cancer. 2015 Dec 1;121(23):4231–4239. doi: 10.1002/cncr.29642
   PubMed Web of Science ®Google Scholar
• Kim H, Rajagopalan MS, Beriwal S, et al. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases. Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):556–563. doi: 10.1016/j.ijrobp.2014.10.055
   PubMed Web of Science ®Google Scholar
• Sher DJ, Parikh RB, Mays-Jackson S, et al. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer. Am J Clin Oncol. 2014;37(3):215–221. doi: 10.1097/COC.0b013e31827a7d2a
   PubMed Web of Science ®Google Scholar
• Mitera G, Swaminath A, Rudoler D, et al. Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non-small-cell lung cancer. J Oncol Pract. 2014 May;10(3):e130–6. doi: 10.1200/JOP.2013.001206
   PubMedGoogle Scholar
• Louie AV, Rodrigues GB, Palma DA, et al. Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada. Oncology. 2014 Aug;19(8):880–885. doi: 10.1634/theoncologist.2013-0469
   Google Scholar
• Hall MD, McGee JL, McGee MC, et al. Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases. J Neurosurg. 2014 Dec;121(Suppl:84–90):84–90. doi: 10.3171/2014.7.GKS14972
   PubMedGoogle Scholar
• Vuong DA, Rades D, van Eck ATC, et al. Comparing the cost-effectiveness of two brain metastasis treatment modalities from a payer’s perspective: stereotactic radiosurgery versus surgical resection. Clin Neurol Neurosurg. 2013 Mar;115(3):276–284. doi: 10.1016/j.clineuro.2012.05.005
   PubMed Web of Science ®Google Scholar
• Shah A, Hahn SM, Stetson RL, et al. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. Cancer. 2013 Sep;119(17):3123–3132. doi: 10.1002/cncr.28131
   PubMed Web of Science ®Google Scholar
• Lincy LS, Byfield SD, Chang EL, et al. Cost-effectiveness analysis of a randomized study comparing radiosurgery with radiosurgery and whole brain radiation therapy in patients with 1 to 3 brain metastases. American journal of clinical oncology. 2012 Feb 1;35(1):45–50. doi: 10.1097/COC.0b013e3182005a8f
   PubMed Web of Science ®Google Scholar
• Vuong DA, Rades D, Le AN, et al. The cost-effectiveness of stereotactic radiosurgery versus surgical resection in the treatment of brain metastasis in Vietnam from the perspective of patients and families. World Neurosurg. 2012 Feb;77(2):321–328. doi: 10.1016/j.wneu.2011.05.050
   PubMed Web of Science ®Google Scholar
• Puri V, Crabtree TD, Kymes S, et al. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis. J Thorac Cardiovasc Surg. 2012;143(2):428–436. doi: 10.1016/j.jtcvs.2011.10.078
   PubMed Web of Science ®Google Scholar
• Parthan A, Pruttivarasin N, Davies D, et al. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front Oncol. 2012 Aug;2:1–9. doi: 10.3389/fonc.2012.00081
   Google Scholar
• Murphy JD, Chang DT, Abelson J, et al. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer. 2012 Feb 15;118(4):1119–1129. doi: 10.1002/cncr.26365
   PubMed Web of Science ®Google Scholar
• Hodges JC, Lotan Y, Boike TP, et al. Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. J Oncol Pract. 2012 May;8(3 Suppl):e31s–7s. doi: 10.1200/JOP.2012.000548
   PubMedGoogle Scholar
• Sher DJ, Wee JO, Punglia RS. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e767–74. doi: 10.1016/j.ijrobp.2010.10.074
   PubMed Web of Science ®Google Scholar
• Grutters JPC, Pijls-Johannesma M, De Ruysscher D, et al. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev. 2010 Oct;36(6):468–476. doi: 10.1016/j.ctrv.2010.02.018
   PubMed Web of Science ®Google Scholar
• Papatheofanis FJ, Williams E, Chang SD. Cost-utility analysis of the cyberknife system for metastatic spinal tumors. Neurosurgery. 2009 Feb;64(2 Suppl):A73–83. doi: 10.1227/01.NEU.0000341205.37067.DE
   PubMed Web of Science ®Google Scholar
• Verma V, Yegya-Raman N, Sprave T, et al. A systematic review of the cost-effectiveness of stereotactic radiation therapy for cancer oligometastases. Int J Radiat Oncol Biol Phys. 2022;114(5):977–988. doi: 10.1016/j.ijrobp.2022.05.042
   PubMed Web of Science ®Google Scholar
• FhdA M, Rozman LM, HdA C, et al. Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancer. Cost Eff Resour Alloc. 2023 Jan 16;21(1):4. doi: 10.1186/s12962-023-00415-1
   PubMed Web of Science ®Google Scholar
• Sun H, Jin C, Wang H, et al. Cost-effectiveness of stereotactic body radiotherapy in the treatment of non–small-cell lung cancer (NSCLC): a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2022;22(5):723–734. doi: 10.1080/14737167.2022.2050217
   PubMed Web of Science ®Google Scholar